ClinicalTrials.gg
CompletedNCT01299597Updated Jul 21, 2017

A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of SB-649868 on the Pharmacokinetics of Simvastatin and Atorvastatin in Healthy Male Volunteers.

A Phase 1 interventional study of Atorvastatin and Simvastatin in Sleep Disorders, sponsored by GlaxoSmithKline. Completed at 1 site in Germany. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-21.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2010, registered Jul 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Sleep Wake Disorders with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Sleep Wake Disorders · Germany.

Enrollment
12th of 15
30 · median 57
Started
2010
with 3 others
Phase 1
2 of 24
none open now
Registered
7th of 24
by date
Lead sponsor
3 of 24
GlaxoSmithKline

Among the 24 studies in Sleep Wake Disorders with a site in Germany, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2010, is one of 2 in phase 1, and was the 7th registered.

Sleep Wake Disorders

747 studies on the registry are indexed under Sleep Wake Disorders; 182 are open to participants now.

Browse Sleep Wake Disorders studies →

Open to participants now

4 of the 24 studies in Sleep Wake Disorders with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 110 Sleep Wake Disorders studies recruiting now, 36 (33%) set no upper age limit and 54 (49%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Sleep Wake Disorders with a site in Germany, or all of them as a file.
02

Study summary

The present study will investigate in humans the enzyme inhibition effects of SB-649868 on CYP3A4, using Simvastatin and Atorvastatin as CYP3A4 probe substrates, administered as single doses: alone, and on two different occasions after repeat doses of SB-649868, at the same time as SB-649868 and 2h before SB-649868.

03

Conditions studied

  • Sleep Disorders

Browse trials for

Keywords

  • repeat dose
  • statins
  • safety and tolerability
  • drug interaction
  • sb649868
  • healthy male subjects
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subject, as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, neuropsychiatric status using the MINI International Neuropsychiatric Interview, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. However,

    • Subjects with cTpn I values above 99th percentile of normal range of the selected assay should always be excluded from enrollment;
    • Subjects with alkaline phosphatase or > 1.5xULN should always be excluded (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%);
  2. Male between 18 and 65 years of age inclusive, at the time of signing the .
  3. Body weight ≥50 kg and within the range 18.5-29.9 kg/m2 inclusive.
  4. Subjects must agree to use one of the methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 3 days post last dose (equivalent to 5 terminal half-lives post-last dose).
  5. Having given written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant psychiatric neurological, musculo-skeletal , respiratory, gastrointestinal, hepatic, uncontrolled hypothyroidism. pancreatic or renal diseases or of any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  2. Subjects, who in the Investigator's judgement, pose a significant suicide risk. Evidence of serious suicide risk may include any history of suicidal behaviour and/or any suicidal ideation of type 4 or 5 on the C-SSRS in the last 6 months.
  3. History of cardiovascular diseases and/or evidence of repolarization defects.
  4. Family history of heriditary muscular disorders.
  5. Subjects with abnormal defined as: average or QTcF > 450 msec; PQ \< 120 ms or > 220 ms; complete left bundle branch block; second-or third-degree AV block; any relevant ST/T wave abnormalities ; any atrial or ventricular arrhtymias which are of clinical significance as determined by the Investigator.
  6. History of regular alcohol consumption within 6 months of the study defined as:

    • an average weekly intake of greater than 21 units (14 units for female) or an average daily intake of greater than 3 units (2 units for female). 1 unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.
  7. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  8. Vulnerable subjects, or subject is mentally or legally incapacitated, or has language barrier precluding adequate understanding of cooperation.
  9. A positive pre-study surface antigen or positive antibody result within 3 months of screening
  10. A positive test for antibody.
  11. A positive pre-study drug/alcohol screen.
  12. Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  13. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  14. Consumption of broccoli, radish sprouts, cauliflower, cabbage, orange juice, apple juice grapefruit juice or grapefruit within 7 days prior to the first dose of study medication until collection of the final pharmacokinetic blood sample.
  15. The subject has participated in a clinical trial and has received an product (IP) within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the IP (whichever is longer).
  16. Exposure to more than four new chemical entities (i.e., medical drugs being under development) within 12 months prior to the first dosing day.
  17. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  18. Unwillingness or inability to follow the procedures outlined in the protocol.
  19. The subject is unable or unwilling to abstain from strenuous physical activity in the 48 h before screening and up to the follow up visit.
  20. Subject is the investigator or his/her deputies, research assistant, pharmacist, study coordinator, other staff or relative thereof involved in the conduct of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1: Atorvastatin

    single dose session with Atorvastatin with PK samples collected up to 72h post dose, then 14 days repeat dose session with SB649868 with Atorvastatin single dose co-administered on day 8 (same time as SB649868) and on day 12 (2 hours before SB649868).

    Drug: Atorvastatin · Drug: SB649868

  • Experimental
    Cohort 2: Simvastatin

    single dose session with Simvastatin with PK samples collected up to 24h post dose, then 14 days repeat dose session with SB649868 with Simvastatin single dose co-administered on day 12 (same time as SB649868) and on day 14 (2 hours before SB649868).

    Drug: Simvastatin · Drug: SB649868

Interventions

  • 20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.

  • 10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.

  • 20mg daily given for 14 days.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability evaluated by adverse event monitoring, ECG, Vital Signs, physical examination, laboratory values and Romberg/heel to toe tests; plasma analysis of Simvastatin and Atorvastatin and active metabolites.

    Time frame: screening period of 28 days followed 17 days clinical duration plus a follow up visit 7-14 days post last dose

07

Study locations

1 site
  • GSK Investigational Site
    Berlin, 14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2010 to primary completion in Feb 2010, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2010
First posted
Feb 18, 2011
StartActual
Jan 18, 2010
Primary completionActual
Feb 26, 2010
CompletionActual
Feb 26, 2010
Last update
Jul 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01299597
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 18, 2011
Start date
Jan 18, 2010
Primary completion
Feb 26, 2010
Completion
Feb 26, 2010
Last update
Jul 21, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Simvastatin · SB-649868

Start the discussion